GPT Healthcare Limited (NSE: GPTHEALTH) reported its unaudited financial results for Q1 FY27, showing a robust performance with total income at Rs 128 crore, marking an 18% year-on-year growth. The company’s EBITDA surged by 38.5% to Rs 26.2 crore, while the Profit After Tax (PAT) increased by 65.7% to Rs 12.7 crore.

Operational Highlights

The company maintained a competitive and affordable Average Room Price per Bed Occupied (ARPOB) at INR 42,350, with occupancy rates at 58.07% (excluding the newly commenced Raipur facility). Including Raipur, the overall occupancy stands at 45.5%.

Key Achievements

ILS Dum Dum completed over 700+ renal transplants, while ILS Howrah launched Robotic Knee Surgery using the MAKO system. ILS Agartala delivered over 700 radiation therapy procedures, and ILS Salt Lake surpassed 800 robotic surgeries. ILS Raipur received its liver transplant license and is expected to break even by Q3 FY27.

Dr. Om Tantia, Chairman of GPT Healthcare, commented, ‘During the quarter, GPT Healthcare continued to advance its long-term growth strategy by improving occupancy across mature hospitals, progressively ramping up newer facilities, and strengthening its presence in underserved, high-density markets.’ The company is also finalizing its seventh hospital, expected to increase the network’s total capacity to more than 1,000 beds.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of GPT Healthcare Limited

GPT Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

GPT rises 14.7% over three months, with buying pressure holding steady. The PEG stands at 11.78 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Buyers show up with 2.2x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 14.7% in three months on 9.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of GPT Healthcare Limited.

GPT Healthcare Limited (NSE: GPTHEALTH) reported its financial results for the financial year ended March 31, 2026, showcasing a robust performance. The company’s revenue for Q4 FY26 stood at Rs. 128.0 crore, marking a significant 24.30% year-on-year growth.

Financial Highlights

The company’s total revenue for FY26 was Rs. 478.5 crore, reflecting a 15.14% increase from the previous year. EBITDA for the quarter was Rs. 25.0 crore, up by 12.27% y-o-y, while the Profit After Tax (PAT) reached Rs. 14.7 crore, showing a 13.00% growth. Despite the positive revenue and profit growth, the EBITDA margin slightly declined to 19.53% from 21.62% in the same quarter last year.

Operational Achievements

The company maintained a competitive Average Revenue Per Occupied Bed (ARPOB) at INR 39,243, while achieving a steady improvement in occupancy rates at 55.90% (excluding the newly commenced Raipur facility). Including Raipur, the overall occupancy stands at 45.87%. The Raipur Hospital successfully commenced operations, and new services like Respiratory ICU and cardiac care were launched in ILS Dum Dum. Additionally, cutting-edge robotic surgical technology was installed in Salt Lake and Howrah Hospital, with over 800 robotic surgeries performed.

Future Prospects

Looking ahead, GPT Healthcare Limited plans to commission a 150-bed facility in Jamshedpur by the end of FY27. The company’s strategic initiatives aim to enhance its clinical and technological leadership, ensuring continued growth and improved patient care.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of GPT Healthcare Limited

GPT Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

GPT moves sideways over three months, with neither buyers nor sellers taking control. The PEG stands at 4.53 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 9.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. Revenue grows at 6.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of GPT Healthcare Limited.